467 related articles for article (PubMed ID: 22995901)
21. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
22. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
[TBL] [Abstract][Full Text] [Related]
23. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.
Unterholzner S; Willhauck MJ; Cengic N; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2006 Jan; 91(1):69-78. PubMed ID: 16234306
[TBL] [Abstract][Full Text] [Related]
24. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
26. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
27. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Romijn JA; van der Heide D
Exp Clin Endocrinol Diabetes; 2001; 109(1):52-5. PubMed ID: 11573141
[TBL] [Abstract][Full Text] [Related]
28. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
Dohán O; De la Vieja A; Carrasco N
Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
[TBL] [Abstract][Full Text] [Related]
29. Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma.
Gaertner FC; Rohde F; Mueller J; Blechert B; Janssen KP; Essler M
Int J Cancer; 2009 Dec; 125(12):2783-91. PubMed ID: 19569179
[TBL] [Abstract][Full Text] [Related]
30. Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor.
Li W; Venkataraman GM; Ain KB
J Clin Endocrinol Metab; 2007 Mar; 92(3):1080-7. PubMed ID: 17164311
[TBL] [Abstract][Full Text] [Related]
31. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells.
Spitzweg C; Scholz IV; Bergert ER; Tindall DJ; Young CY; Göke B; Morris JC
Endocrinology; 2003 Aug; 144(8):3423-32. PubMed ID: 12865321
[TBL] [Abstract][Full Text] [Related]
32. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
Chai W; Ye F; Zeng L; Li Y; Yang L
J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
[TBL] [Abstract][Full Text] [Related]
33. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Zarnegar R; Brunaud L; Kanauchi H; Wong M; Fung M; Ginzinger D; Duh QY; Clark OH
Surgery; 2002 Dec; 132(6):984-90; discussion 990. PubMed ID: 12490845
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.
Kogai T; Hershman JM; Motomura K; Endo T; Onaya T; Brent GA
Endocrinology; 2001 Aug; 142(8):3369-79. PubMed ID: 11459780
[TBL] [Abstract][Full Text] [Related]
35. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
Schmutzler C; Köhrle J
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
[TBL] [Abstract][Full Text] [Related]
37. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter.
Scholz IV; Cengic N; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2004 Mar; 89(3):1108-16. PubMed ID: 15001595
[TBL] [Abstract][Full Text] [Related]
38. Effect of oxygen concentrations on sodium iodide symporter expression and iodide uptake and hCG expression in human choriocarcinoma BeWo cells.
Li H; Landers K; Patel J; Richard K; Mortimer RH
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1085-91. PubMed ID: 21406611
[TBL] [Abstract][Full Text] [Related]
39. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.
Presta I; Arturi F; Ferretti E; Mattei T; Scarpelli D; Tosi E; Scipioni A; Celano M; Gulino A; Filetti S; Russo D
BMC Cancer; 2005 Jul; 5():80. PubMed ID: 16029487
[TBL] [Abstract][Full Text] [Related]
40. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
